{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:35:13Z","timestamp":1760060113611,"version":"build-2065373602"},"reference-count":48,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Despite therapeutic advances, morbidity and mortality remain high in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), primarily due to increased cardiovascular risk. Objectives: Our study aimed to evaluate the cardiovascular risk profile and biomarker dynamics in patients with RA and PsA treated with Janus kinase inhibitors (JAKis). To our knowledge, this is the first study assessing Lp(a) levels in this context. Methods: This prospective, observational study assessed 48 adult patients. The follow-up period was 12 months. Traditional cardiovascular risk factors and biological markers, including lipid profile, lipoprotein(a) [Lp(a)], and uric acid (UA), were assessed at baseline and follow-up. Correlations between JAKi therapy, lipid profile changes, and cardiovascular risk factors were investigated. Cox regression analysis was used to identify predictors of non-major cardiovascular events. Results: A strong positive correlation was observed between baseline and 12-month Lp(a) levels (r = 0.926), despite minor statistical shifts. No major cardiovascular events occurred during follow-up; however, 47.9% of patients experienced non-major cardiovascular events (e.g., uncontrolled arterial hypertension, exertional angina, and new-onset arrhythmias). Active smoking [hazard ratio (HR) 9.853, p = 0.005], obesity (HR 3.7460, p = 0.050), and arterial hypertension (HR 1.219, p = 0.021) were independent predictors of these events. UA (HR 1.515, p = 0.040) and total cholesterol (TC) (HR 1.019, p = 0.034) were significant biochemical predictors as well. Elevated baseline Lp(a) combined with these factors was associated with an increased event rate, particularly after age 60. Conclusions: Traditional cardiovascular risk factors remain highly prevalent and predictive, underscoring the need for comprehensive cardiovascular risk management. Lp(a) remained stable and may serve as a complementary biomarker for risk stratification in JAKi-treated patients.<\/jats:p>","DOI":"10.3390\/jcm14155433","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T08:46:55Z","timestamp":1754383615000},"page":"5433","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Risk in Rheumatic Patients Treated with JAK Inhibitors: The Role of Traditional and Emerging Biomarkers in a Pilot Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Diana","family":"Popescu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"IIIrd Internal Medicine Clinic, \u201cSaint Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8942-1909","authenticated-orcid":false,"given":"Minerva Codruta","family":"Badescu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"IIIrd Internal Medicine Clinic, \u201cSaint Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8175-2583","authenticated-orcid":false,"given":"Elena","family":"Rezus","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Physiotherapy, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"Rheumatology Clinic, Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7144-2506","authenticated-orcid":false,"given":"Daniela Maria","family":"Tanase","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"IIIrd Internal Medicine Clinic, \u201cSaint Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8923-8194","authenticated-orcid":false,"given":"Anca","family":"Ouatu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"IIIrd Internal Medicine Clinic, \u201cSaint Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8276-835X","authenticated-orcid":false,"given":"Nicoleta","family":"Dima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"IIIrd Internal Medicine Clinic, \u201cSaint Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana-Nicoleta","family":"Buliga-Finis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"IIIrd Internal Medicine Clinic, \u201cSaint Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-9306","authenticated-orcid":false,"given":"Evelina Maria","family":"Gosav","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"IIIrd Internal Medicine Clinic, \u201cSaint Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiana","family":"Costin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Physiotherapy, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"Rheumatology Clinic, Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-7325","authenticated-orcid":false,"given":"Ciprian","family":"Rezus","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"IIIrd Internal Medicine Clinic, \u201cSaint Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.berh.2018.10.005","article-title":"Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis","volume":"32","year":"2018","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, Regional and National Burden of RheumaToid Arthritis 1990\u20132017: A Systematic analysis of The Global Burden of Disease Study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s42358-019-0084-6","article-title":"Relationship of rheumatoid arthritis and coronary artery disease in the Korean population: A nationwide cross-sectional study","volume":"59","author":"Lee","year":"2019","journal-title":"Adv. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"E58","DOI":"10.1016\/S2665-9913(20)30221-6","article-title":"Cardiovascular risk in inflammatory arthritis: Rheumatoid arthritis and gout","volume":"3","author":"Hansildaar","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.autrev.2021.102925","article-title":"Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus","volume":"21","author":"Restivo","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.15420\/ecr.2020.44","article-title":"Atherosclerotic cardiovascular disease in rheumatoid arthritis: Impact of inflammation and antirheumatic treatment","volume":"16","author":"Kerola","year":"2021","journal-title":"Eur. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1016\/j.jacc.2021.04.052","article-title":"Systematic Coronary Risk Evaluation (SCORE): JACC Focus Seminar 4\/8","volume":"77","author":"Graham","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Sharma, A., Christodorescu, R., Agbariah, A., Duda-Seiman, D., Dahdal, D., Man, D., Kundnani, N.R., Cretu, O.M., and Dragan, S. (2022). Cardiovascular risk prediction parameters for better management of rheumatic diseases. Heathcare, 10.","DOI":"10.3390\/healthcare10020312"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejim.2021.10.001","article-title":"Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the cardiovascular obesity and rheumatic disease (CORDIS) study group","volume":"96","author":"Cacciapaglia","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systematic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: A randomized controlled trial","volume":"72","author":"Giles","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_13","first-page":"119","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: A post hoc analysis from ORAL Surveillance","volume":"81","author":"Buch","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/acr.23875","article-title":"Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"72","author":"Singht","year":"2020","journal-title":"Arthritis Care Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"154461","DOI":"10.1016\/j.metabol.2020.154461","article-title":"Advances in biologic therapy for dyslipidemias and atherosclerosis","volume":"116","author":"Valanti","year":"2020","journal-title":"Metab. Clin. Exp."},{"key":"ref_16","first-page":"182","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: A nationwide cohort study","volume":"74","author":"Hoisnard","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13075-023-03154-z","article-title":"Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: Post hoc analysis of phase II\/III trials","volume":"25","author":"Tesser","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/rheumatology\/keae012","article-title":"Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: Results of a long-term study","volume":"63","author":"Caporali","year":"2024","journal-title":"Rheumatology"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sanmarti, R., and Coromias, H. (2023). Upadacitinib for patients with rheumatoid arthritis: A comprehensive review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051734"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Harrington, R., Harkins, P., and Conway, R. (2023). Janus kinase inhibitors in rheumatoid arthritis: An update on the efficacy and safety of tofacitinib, baricitinib and upadacitinib. J. Clin. Med., 12.","DOI":"10.3390\/jcm12206690"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Calvo-Garcia, A., Herraiz, E.R., Cubas, I.M.L., De Dios, B.V., Gonzalez, J.B., Baladron, A.M., and Garcia-Vicuna, R. (2024). The real-world effectiveness, persistence, adherence, and safety of Janus kinase inhibitor baricitinib in rheumatoid arthritis: A long-term study. J. Clin. Med., 13.","DOI":"10.20944\/preprints202403.1760.v1"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Martinez-Molina, C., Gich, I., Diaz-Torne, C., Park, H.S., Feliu, A., Vidal, S., and Coromias, H. (2024). Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: A real-world study. Sci. Rep., 14.","DOI":"10.1038\/s41598-023-50379-8"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yan, J., Yang, S., Han, L., Ba, X., Shen, P., Lin, W., Li, T., Zhang, R., Huang, Y., and Huang, Y. (2023). Dyslipidemia in rheumatoid arthritis: The possible mechanisms. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1254753"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kotyla, P.J., Islam, A., and Engelmann, M. (2020). Clinical aspects of Janus kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197390"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wei, Q., Wang, H., Zhao, J., Luo, Z., Wang, C., Zhu, C., Su, N., and Zhang, S. (2023). Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: Systematic review and network meta-analysis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1237234"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1311947","DOI":"10.1016\/j.ijcard.2024.131947","article-title":"Association of serum concentration of remnant cholesterol with incident cardiovascular disease in patients with rheumatoid arthritis: A real-world data from 2001 to 2022","volume":"405","author":"Zou","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rogriguez-Gonzalez, D., Garcia-Gonzalez, M., Gomez-Bernal, F., Quevedo-Abeledo, J.C., Gonzalez-Rivero, A.F., Jimenez-Sosa, A., Gonzalez-Lopez, E., Heras-Recuero, E., Ocejo-Vinyls, J.G., and Gonzalez-Gay, M.A. (2024). Relationship between the complement system and serum lipid profile in patients with rheumatoid arthritis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1420292"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/art.40889","article-title":"Exploring the lipid paradox theory in rheumatoid arthritis: Associations of low circulating low-density lipoprotein concentration with subclinical coronary atherosclerosis","volume":"71","author":"Giles","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Chang, C.K., Li, Y.C., Chen, P.K., Chang, S.H., and Chen, D.Y. (2024). Elevated remnant cholesterol as a potential predictor for cardiovascular events in rheumatoid arthritis patients. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1449219"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"152274","DOI":"10.1016\/j.semarthrit.2023.152274","article-title":"Elevated triglycerides levels are associated with increased risk for major adverse cardiovascular events in statin-na\u00efve rheumatoid arthritis patients: A nationwide cohort study","volume":"63","author":"Choi","year":"2023","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Vinci, P., Di Girolamo, F.G., Panizon, E., Tosoni, L.M., Cerrato, C., Pellicori, F., Altamura, N., Pirulli, A., Zaccari, M., and Biasinutto, C. (2023). Lipoprotein(a) as a risk factors for cardiovascular diseases: Pathophysiology and treatment perspectives. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20186721"},{"key":"ref_32","first-page":"749","article-title":"Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project","volume":"2","author":"Costaneda","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESR) and the European Stroke Organization (ESO)","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/AphA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10067-022-06415-5","article-title":"Cardiovascular risks associated with Janus kinase inhibitors: Peering outside the black box","volume":"42","author":"Misra","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/1744666X.2022.2039630","article-title":"Safety of JAK inhibitors: Focus on cardiovascular and thromboembolic events","volume":"18","author":"Atzeni","year":"2022","journal-title":"Exp. Rev. Clin. Immunol."},{"key":"ref_37","first-page":"e984","article-title":"Obesity and cardiovascular disease: A scientific statement from the American Heart Association","volume":"143","author":"Poirier","year":"2021","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s42358-019-0089-1","article-title":"High prevalence of obesity in rheumatoid arthritis patients: Association with disease activity, hypertension, dyslipidemia and diabetes, a multi-center study","volume":"59","author":"Rodrigues","year":"2019","journal-title":"Adv. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"102786","DOI":"10.1016\/j.autrev.2021.102786","article-title":"Risk factors for hypertension in rheumatoid arthritis patients: A systematic review","volume":"20","author":"Hadwen","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cophys.2020.09.016","article-title":"The role of inflammation in hypertension: Novel concepts","volume":"19","author":"Patrick","year":"2021","journal-title":"Curr. Opin. Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1759720X211030809","DOI":"10.1177\/1759720X211030809","article-title":"Factors associated with risk of major adverse cardiovascular events in patients with rheumatoid arthritis: A nationwide, population-based, case-control study","volume":"13","author":"Chen","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_42","first-page":"234","article-title":"Changes in the cholesterol profile of patients with rheumatoid arthritis treated with biologics or Janus kinase inhibitors","volume":"30","author":"Koh","year":"2023","journal-title":"J. Rheumatol. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10067-021-06003-z","article-title":"Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: A systematic review and network meta-analysis","volume":"41","author":"Li","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ma, X.N., Shi, M.F., Wang, S.I., Feng, W., Chen, S.L., Zhong, X.Q., Liu, Q.P., Cheng-Chung Wei, J., Lin, C.S., and Xu, Q. (2024). Risk of dyslipidemia and major adverse cardiac events with tofacitinib versus adalimumab in rheumatoid arthritis: A real-world cohort study from 7580 patients. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1370661"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2017-212461","article-title":"Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies","volume":"77","author":"Taylor","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Tsioulos, G., Kounatidis, D., Vallianou, N.G., Poulaki, A., Kotsi, E., Christodoulatos, G.S., Tsilingiris, D., Karampela, I., Skourtis, A., and Dalamaga, M. (2024). Lipoprotein(a) and atherosclerotic cardiovascular disease: Where do we stand?. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063537"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J. Clin. Lipidol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5433\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:21:19Z","timestamp":1760034079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":48,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14155433"],"URL":"https:\/\/doi.org\/10.3390\/jcm14155433","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}